Koers Carbylan Therapeutics Inc Nasdaq
Aandelen
US1413841073
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | 14,95 mln. 13,84 mln. | Marktkapitalisatie | 493 mln. 456 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -114 mln. -106 mln. | Nettowinst (verlies) 2025 * | -111 mln. -103 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 218 mln. 202 mln. | Nettoliquiditeiten 2025 * | 105 mln. 96,94 mln. | EV/omzet 2025 * | 26 x |
K/w-verhouding 2024 * |
-3,84
x | K/w-verhouding 2025 * |
-4,84
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,77% |
Recentste transcriptie over Carbylan Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 26-03-04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01-08-16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 03-05-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 01-02-19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01-08-16 |
Albert Cha
BRD | Director/Board Member | 51 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,82% | 91,94 mld. | |
-1,32% | 38,74 mld. | |
-12,88% | 32,82 mld. | |
+64,77% | 26,66 mld. | |
-16,31% | 15,32 mld. | |
-5,78% | 13,3 mld. | |
-11,38% | 11,65 mld. | |
-49,84% | 10,12 mld. | |
+5,24% | 9,06 mld. |